Stock Price Movement and Market Context
On 28 Jan 2026, Lincoln Pharmaceuticals Ltd’s share price touched an intraday low of Rs.439.95, representing a 2.23% decline during the trading session. The stock closed with a day change of -1.31%, underperforming the Pharmaceuticals & Biotechnology sector by 1.49%. This marks the third consecutive day of losses, with the stock falling by 3.44% over this period. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market showed resilience on the same day. The Sensex opened flat but gained 354.62 points to close at 82,246.98, a 0.48% increase. The index remains 4.76% below its 52-week high of 86,159.02. Mega-cap stocks led the rally, while Lincoln Pharmaceuticals, a mid-cap player, lagged behind significantly.
Long-Term Performance and Financial Indicators
Over the past year, Lincoln Pharmaceuticals has delivered a total return of -34.99%, considerably underperforming the Sensex’s 8.39% gain. The stock’s 52-week high was Rs.804.70, highlighting the extent of the decline. The company’s long-term growth metrics have been subdued, with net sales growing at an annualised rate of 9.21% and operating profit increasing by only 5.37% over the last five years.
Recent quarterly results have also reflected a challenging environment. The company reported a profit after tax (PAT) of Rs.19.98 crores for the quarter ended September 2025, down 24.1% year-on-year. Profit before tax excluding other income (PBT less OI) stood at Rs.21.58 crores, a decline of 12.98%. Return on capital employed (ROCE) for the half-year was at a low 15.46%, indicating pressure on capital efficiency.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Valuation and Shareholding Insights
Despite the recent price decline, Lincoln Pharmaceuticals maintains a Price to Book Value ratio of approximately 1.3, which is considered fair relative to its peers’ historical valuations. The company’s return on equity (ROE) stands at 11.2%, suggesting moderate profitability for shareholders. Additionally, the company’s average debt-to-equity ratio is effectively zero, indicating a conservative capital structure with minimal leverage.
However, domestic mutual funds hold no stake in Lincoln Pharmaceuticals, a notable point given their capacity for detailed company research. This absence of institutional ownership may reflect reservations about the company’s current valuation or business prospects.
Comparative Performance and Market Position
Lincoln Pharmaceuticals has underperformed not only in the past year but also over longer periods. The stock has lagged behind the BSE500 index over the last three years, one year, and three months. Profitability has also declined, with profits falling by 17.2% over the past year, compounding the negative sentiment around the stock.
The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance. While some peers have benefited from sector tailwinds, Lincoln Pharmaceuticals’ share price trajectory and financial results have not mirrored these trends.
Holding Lincoln Pharmaceuticals Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Rating Update
Lincoln Pharmaceuticals currently holds a Mojo Score of 37.0, categorised as a Sell rating. This represents an upgrade from its previous Strong Sell grade, which was revised on 5 Aug 2025. The company’s market capitalisation grade is rated 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector.
The downgrade in rating over recent months aligns with the stock’s declining price and subdued financial performance. The rating change indicates a reassessment of the company’s growth prospects and risk profile by market analysts.
Summary of Key Metrics
To summarise, Lincoln Pharmaceuticals Ltd’s stock has declined to Rs.439.95, its lowest level in 52 weeks, amid a backdrop of underwhelming financial results and limited institutional interest. The stock’s performance contrasts with broader market gains and sector trends, with key financial indicators such as PAT, PBT, and ROCE showing declines. Valuation metrics remain reasonable, supported by a low debt profile and moderate ROE, but the overall market sentiment remains cautious.
The stock’s trading below all major moving averages and its sustained negative returns over multiple timeframes highlight the challenges faced by the company in regaining investor confidence.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
